Multiplex Antibody Analysis of IgM, IgA and IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts
Por:
Dobaño C, Alonso S, Vidal M, Jiménez A, Rubio R, Santano R, Barrios D, Pons Tomas G, Melé Casas M, Hernández García M, Girona M, Puyol L, Baro B, Millat-Martínez P, Ajanovic S, Balanza N, Arias S, Rodrigo Melero N, Carolis C, García-Miquel A, Bonet-Carné E, Claverol J, Cubells M, Fortuny-Guasch C, Fumadó V, Codina-Bergadà A, Bassat Q, Munoz-Almagro C, Fernández de Sevilla-Estrach M, Gratacós E, Izquierdo L, García-García JJ, Aguilar R, Jordán-García I and Moncunill G
Publicada:
27 ene 2022
Resumen:
COVID-19 affects children to a lesser extent than adults but they can still get infected and transmit SARS-CoV-2 to their contacts. Field deployable non-invasive sensitive diagnostic techniques are needed to evaluate the infectivity dynamics of SARS-CoV-2 in pediatric populations and guide public health interventions, particularly if this population is not fully vaccinated. We evaluated the utility of high-throughput Luminex assays to quantify saliva IgM, IgA and IgG antibodies against five SARS-CoV-2 spike (S) and nucleocapsid (N) antigens in a contacts and infectivity longitudinal study in 122 individuals (52 children and 70 adults). We compared saliva versus serum/plasma samples in infected children and adults diagnosed by weekly RT-PCR over 35 days (n=62), and those who consistently tested negative over the same follow up period (n=60), in the Summer of 2020 in Barcelona, Spain. Saliva antibody levels in SARS-CoV-2 RT-PCR positive individuals were significantly higher than in negative individuals and correlated with those measured in sera/plasmas. Asymptomatic infected individuals had higher levels of anti-S IgG than symptomatic individuals, suggesting a protective anti-disease role for antibodies. Higher anti-S IgG and IgM levels in serum/plasma and saliva, respectively, in infected children compared to infected adults could also be related to stronger clinical immunity in them. Among infected children, males had higher levels of saliva IgG to N and RBD than females. Despite overall correlation, individual clustering analysis suggested that responses that may not be detected in blood could be patent in saliva, and vice versa.In conclusion, measurement of SARS-CoV-2-specific saliva antibodies should be considered as a complementary non-invasive assay to serum/plasma to determine COVID-19 prevalence and transmission in pediatric populations before and after vaccination campaigns.
Filiaciones:
Dobaño C:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Consorcio de Investigación Biomédica en Red (CIBER) de Enfermedades Infecciosas, Madrid, Spain
Alonso S:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Vidal M:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Jiménez A:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Rubio R:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Santano R:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Barrios D:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
:
Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain
Melé Casas M:
Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain
:
Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain
Girona M:
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
Puyol L:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Baro B:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Millat-Martínez P:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Ajanovic S:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Balanza N:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Arias S:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Rodrigo Melero N:
Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain
Carolis C:
Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain
:
Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), Universitat de Barcelona, Barcelona, Spain
Bonet-Carné E:
Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), Universitat de Barcelona, Barcelona, Spain
Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Universitat Politècnica de Catalunya, BarcelonaTech, Barcelona, Spain
Claverol J:
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Fundació Sant Joan de Déu, Barcelona, Spain
Cubells M:
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Fundació Sant Joan de Déu, Barcelona, Spain
Fortuny-Guasch C:
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain
Fumadó V:
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain
Codina-Bergadà A:
Biobank Hospital Sant Joan de Déu, Barcelona, Spain
Bassat Q:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
Catalan Institution for research and Advanced Studies (ICREA), Barcelona, Spain
Munoz-Almagro C:
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Department of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
Molecular Microbiology Department, Hospital Sant Joan de Déu, Esplugues, Spain
Fernández de Sevilla-Estrach M:
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Gratacós E:
Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), Universitat de Barcelona, Barcelona, Spain
Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Center for Biomedical Research on Rare Diseases (CIBER-ER), Madrid, Spain
Izquierdo L:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Consorcio de Investigación Biomédica en Red (CIBER) de Enfermedades Infecciosas, Madrid, Spain
García-García JJ:
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Aguilar R:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Jordán-García I:
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Institut de Recerca Sant Joan de Déu, Esplugues, Spain
Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
Moncunill G:
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
Consorcio de Investigación Biomédica en Red (CIBER) de Enfermedades Infecciosas, Madrid, Spain
Green Published, Green Submitted, gold
|